Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

By afschroeder • August 25, 2026

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano G, Cortés J, Garcia-Fructuoso I, Aftimos P, Bermejo de Las Heras B, Tolosa P, Yuan Y, Valero V, Lipsyc-Sharf M, Muñoz Romero P, Koraichi Auriol F, Paoli A, Crozier JA, Wasserman T, Kaklamani V. Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE. Clin Cancer Res. 2026 Aug 24. doi: 10.1158/1078-0432.CCR-26-1816. Epub ahead of print. PMID: 42635598.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Insights on supplement use during cancer care from online Reddit conversations

Waissengrin B, O'Connor K, Shirazipour CH, Ivan FA, Reckamp KL, Gonzalez-Hernandez G, Figueiredo JC. Insights on supplement use during cancer care from online Reddit conversations.[...]

South Asian Cardiovascular Risk: Role of Coronary Artery Calcium Scoring and Computed Tomography Angiography

Kalra DK, Vedamurthy D, Hosadurg N, Goyal A, Gupta M, Pagidipati N, Slipczuk L, Dey D, Mehta A, Joshi P, Baskaran L, Wong N, Virani[...]

Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy

Karlsberg RP, Thummala AR, Elisarraras FX, Golub IS, Cho GW. Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy. J[...]